DrugFeb 1, 2023
SODIUM CHLORIDE 0.9% Sodium Chloride Injection, USP, 100 mL Single-Dose Container bag recall — FDA D-0177-2023
CGMP Deviations: potential for trace amounts of product carryover.
Class IIFDA: TerminatedNephron Sc Inc.
Latest records
Latest recalls — page 294
The newest recall records with useful source details are listed here.
DrugFeb 1, 2023
Pharmacy Innovations PROSTAGLANDIN (PE1) 45MCG (1ML VIAL) INJECTABLE PROSTAGLANDIN E1 recall — FDA D-0234-2023
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class IIFDA: TerminatedPharmacy Innovations
DrugFeb 1, 2023
Glaxosmithkline Consumer Healthcare Holdings DBA Advil Liqui Gels, Solubilized ibuprofen recall — FDA D-0182-2023
Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back
Class IFDA: TerminatedGlaxosmithkline Consumer Healthcare Holdings DBA Haleon
DrugFeb 1, 2023
Pharmacy Innovations METHYLCOBALAMIN 12.5MG/ML (1ML VIAL) INJECTABLE METHYLCOBALAMIN 25MG/ML recall — FDA D-0222-2023
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class IIFDA: TerminatedPharmacy Innovations
DrugFeb 1, 2023
Pharmacy Innovations Cyclosporine (A) 0.1% recall — FDA D-0200-2023
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class IIFDA: TerminatedPharmacy Innovations
DrugFeb 1, 2023
Pharmacy Innovations SEMAGLUTIDE 0.5MG/ML (0.5ML VIAL) INJECTABLE SEMAGLUTIDE 1MG/ML recall — FDA D-0236-2023
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class IIFDA: TerminatedPharmacy Innovations
DrugFeb 1, 2023
Glaxosmithkline Consumer Healthcare Holdings DBA Advil Liqui Gels (minis), Solubilized recall — FDA D-0183-2023
Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back
Class IFDA: TerminatedGlaxosmithkline Consumer Healthcare Holdings DBA Haleon
DrugFeb 1, 2023
Pharmacy Innovations TESTOSTERONE 3% (4GM TUBE) OPHTH OINTME TESTOSTERONE CYP/ANASTROZOLE-GS recall — FDA D-0238-2023
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class IIFDA: TerminatedPharmacy Innovations
DrugFeb 1, 2023
Pharmacy Innovations ESTRADIOL CYP/TEST CYP- SS OIL- 2MG/50MG/ML (1.5ML VIAL) INJECTABLE recall — FDA D-0206-2023
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class IIFDA: TerminatedPharmacy Innovations
DrugFeb 1, 2023
Pharmacy Innovations PE1/PAPAV/ATROP/CHLOPROM** 7MCG/8.7MG/0.1MG/1.8MG/ML (1ML VIAL) recall — FDA D-0227-2023
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class IIFDA: TerminatedPharmacy Innovations
DrugFeb 1, 2023
Pharmacy Innovations PAPAVERINE/PHENTOLAMINE 30MG/0.5MG/ML (1ML VIAL) INJECTABLE recall — FDA D-0226-2023
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class IIFDA: TerminatedPharmacy Innovations
DrugFeb 1, 2023
Pharmacy Innovations THIAMINE/RIBOFLA/NIACINAMI/DEXPANTH/PYRIDOX/HYDROXYCOBAL recall — FDA D-0239-2023
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class IIFDA: TerminatedPharmacy Innovations
DrugFeb 1, 2023
Pharmacy Innovations GENTAMICIN BLADDER 0.08MG/ML (60ML SYRINGE) IRRIGATION recall — FDA D-0209-2023
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class IIFDA: TerminatedPharmacy Innovations
DrugFeb 1, 2023
Spectrum Laboratory Products Epinephrine (L-Adrenaline), USP, CAS 51-43-4, 1 KG amber glass recall — FDA D-0179-2023
Discoloration: Product complaints of the repackaged Epinephrine API being discolored which could result in less effective product
Class IFDA: TerminatedSpectrum Laboratory Products, Inc.
DrugFeb 1, 2023
Preferred Pharmaceuticals Allopurinol Tablets 100mg, USP, 90-count bottles recall — FDA D-0173-2023
Presence of Foreign Substance: manufacturer recalled this re-packaged product due to reports of a small piece of green plastic embedded in the crack towards the edge of the tablet.
Class IIFDA: TerminatedPreferred Pharmaceuticals, Inc.
DrugFeb 1, 2023
Pharmacy Innovations TACROLIMUS 0.03% OPH SOLUTION TACROLIMUS 0.1% (1ML DROPTAINER) OPH recall — FDA D-0237-2023
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class IIFDA: TerminatedPharmacy Innovations
DrugFeb 1, 2023
Pharmacy Innovations VANCOMYCIN FORTIFIED 10MG/ML (1ML DROPTAINER) OPH SOLUTION VANCOMYCIN recall — FDA D-0241-2023
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class IIFDA: TerminatedPharmacy Innovations
DrugFeb 1, 2023
Allopurinol Tablets USP, 100 mg, 100-count bottle recall — FDA D-0168-2023
Presence of Foreign Substance: Presence of a small piece of green plastic embedded in the crack towards the edge of the tablet.
Class IIFDA: TerminatedAccord Healthcare, Inc.
DrugFeb 1, 2023
Pharmacy Innovations PE1/PAPAV/PHEN 20MCG/30MG/2MG/ML (1ML VIAL) INJECTABLE PE1/PAPAV/PHEN recall — FDA D-0228-2023
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class IIFDA: TerminatedPharmacy Innovations
DrugFeb 1, 2023
Pharmacy Innovations METHION/INOSIT/CHOLINE/CYANOCOBAL 25MG/50MG/50MG/1MG/ML (1ML VIAL) recall — FDA D-0220-2023
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class IIFDA: TerminatedPharmacy Innovations
DrugFeb 1, 2023
Pharmacy Innovations GLUTATHIONE L REDUCED 100MG/ML (2ML NEBVL) INHALATION recall — FDA D-0210-2023
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class IIFDA: TerminatedPharmacy Innovations
VehicleJan 31, 2023
Hyundai Motor roof and pillars recall — NHTSA campaign 23V038000
Hyundai Motor America (Hyundai) is recalling certain 2022 Tucson and 2022-2023 Santa Cruz vehicles. The roof moldings may detach.
roof and pillarsHyundai Motor America
VehicleJan 29, 2023
Telluride side/window recall — NHTSA campaign 23V035000
Kia America, Inc. (Kia) is recalling certain 2023 Telluride vehicles. Due to a manufacturing error, the wire harnesses for the second row seat side air bags may become damaged, causing them…
side/windowKia America, Inc.
DrugJan 25, 2023
Rasagiline Mesylate Tablets 1 mg recall — FDA D-0159-2023
Presence of Foreign Substance- A complaint was received of black spots/shiny metallic speck on the tablets.
Class IIFDA: TerminatedAscend Laboratories, LLC
Browse by month
Recent recall archives
Browse recent months with enough recall history for useful comparison.
August 2026149 records · 4 categoriesJuly 2026371 records · 4 categoriesJune 2026375 records · 4 categoriesMay 2026340 records · 4 categoriesApril 2026415 records · 4 categoriesMarch 2026190 records · 4 categoriesFebruary 2026331 records · 4 categoriesJanuary 2026212 records · 4 categoriesDecember 2025389 records · 4 categoriesNovember 2025326 records · 4 categoriesOctober 2025455 records · 4 categoriesSeptember 2025285 records · 4 categories